Patients with a history of, or current grade  depression are not eligible
Prior or current invasive malignancy with current evidence of active disease within the past  years
Inclusion Criteria:\n\n         Patients aged  to <  years with at least one non severe comorbidity ie disease or\n        syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities\n        which could increase the risk of toxicity and/or early death of intensive chemotherapy in\n        the opinion of the investigator and are not contra-indicated for non-intensive\n        chemotherapy.\n\n        or ?  years with or without any comorbidity at the time of the informed consent\n        signature;\n\n         Newly diagnosed, untreated de novo or secondary AML according to WHO classification;\n\n        Exclusion Criteria:\n\n          -  Prior or current treatment with chemotherapy for any myeloid disorder (excluding\n             hydroxyurea) or radiotherapy for extramedullary involvement within  weeks of\n             randomization;\n\n          -  Prior treatment with decitabine, azacitidine, or cytarabine;\n\n          -  Prior malignancies for  years with exception of basal cell, squamous cell carcinoma\n             of the skin, or carcinoma \ in situ \ of the cervix or breast;\n\n          -  Chronic myelogenous or acute promyelocytic leukaemia;\n\n          -  Known CNS involvement;\n\n          -  Patient eligible to bone marrow or stem cell transplant;\n\n          -  WBC ? ./mm;\n\n          -  Impaired renal function with Creatinine clearance <  mL/min/.m according to the\n             MDRD formula;\n\n          -  Serum bilirubin ? . x ULN and/or AST and/or ALT ? . x ULN (upper limit of normal\n             value);\n\n          -  Calcemia ? . mmol/L ( mg/L) at screening assessment (corrected with\n             albuminemia);\n\n          -  History of diseases known to be associated with calcium disorders: ongoing\n             hyperparathyroidism, sarcoidosis.;\n\n          -  Presence or history of symptomatic kidney stones in the last  years;\n\n          -  Hypersensitivity to any of the excipients of decitabine (Potassium dihydrogen\n             phosphate (E) ; Sodium hydroxide (E) ; Hydrochloric acid (for pH adjustment) or\n             to the excipient of inecalcitol tablets (lactose);\n\n          -  Current use of drugs known to influence serum calcium (such as thiazide diuretics,\n             teriparatide, calcitonin and multivitamin supplements containing >  IU of vitamin D\n             or calcium);\n\n          -  Current use of digitalis;\n\n          -  Current use of drugs which could influence bioavailability of inecalcitol (such as\n             magnesium-containing antacids, bile-resin binders);\n\n          -  Use of any other experimental drug or therapy or vitamin D supplementation within \n             weeks of randomization;\n\n          -  Known HIV;\n\n          -  Patients who are eligible for intensive induction therapy with curative intent;\n\n          -  Refractory congestive heart failure;\n\n          -  Active infection resistant to anti-infective therapy;\n\n          -  Documented pulmonary disease with DLCO ? % or FEV? %, or dyspnea at rest or\n             requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm;\n\n          -  Liver cirrhosis Child B or C or acute viral hepatitis;\n\n          -  Current mental illness requiring psychiatric hospitalization, institutionalization or\n             intensive outpatient management, or current cognitive status that produces dependence\n             (as confirmed by the specialist) not controlled by the caregiver;\n\n          -  Uncontrolled neoplasia;
Current enrollment in any other investigational treatment study
Current treatment with oral or parenteral anti-coagulants/antiplatelet agents
Subjects with active HSV- infection on current valacyclovir, acyclovir or ganciclovir therapy must be off treatment with any of these agents at least  days prior to surgery
history of or current cardiac issues
Patients with uncontrolled inter-current illness are excluded
Current active treatment in another clinical study.
History or current diagnosis of Pulmonary Alveolar Proteinosis or Hypoxemia
Current or anti-cancer therapy w/in  wks pre-study or w/Grade ? side effects not resolved w/in  wks pre-study
Uncontrolled inter-current illness
Presence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreated
Current symptom of keratitis or retinopathy at >= grade 
Current use of tobacco product other than cigarettes (e.g. e-cigarettes, smokeless tobacco)
Current use of non-nucleoside reverse transcriptase inhibitors (NNRTI) including efavirenz, rilpivirine, etravirine, delavirdine, nevirapine, and lersivirine
Current use of statins or fibrates for any time during the  months prior to the study
Participants may not have current or history of clinically significant muscle disorders (eg, myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels
Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared
History and/or current evidence of endocrine alteration of calcium-phosphate homeostasis
Presence of current angina;
Undergoing or have plans to undergo changes to current cancer treatment.
Current diagnosis of symptomatic bradycardia
Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared
Serious inter-current medical illness which would interfere with the ability of the patient to carry out the treatment program
Current use of warfarin for any reason; NOTE: if patient can be safely transitioned to another anticoagulant, they may be eligible provided other criteria are satisfied
Patients must not have current evidence of another malignancy that requires treatment
Current active treatment in another clinical study
Current use or anticipated need for alternative, holistic, naturopathic, or botanical formulations used for the purpose of cancer treatment
No uncontrolled, inter-current or recent illness that in the investigators opinion precludes participation in the study, including those undergoing therapy for a separate invasive malignancy
Subjects with bleeding diatheses, thrombocytopenia or current anticoagulant use
Subjects in the combination therapy arms must be eligible to receive erlotinib, or nivolumab per most current prescribing information, or at the discretion of the Investigator.
More than  prior relapses (not counting the current relapse being treated on this study)
Current histologically transformed disease.
Current infection
Current anticoagulant therapy; (acetylsalicylic acid [ASA] =<  mg per day is allowed)
Other malignancy that would interfere with the current intervention
NSCLC cohort only: current smoker
Current use of antibiotic rinses or troches
Current progestin-based hormone replacement therapy.
Current or prior radiation to the left hemithorax
Patients who are on current long term treatment (?  consecutive weeks) with Aspirin, NSAID or Cox- inhibitors
Patient on active current treatment of antiplatelet agents (i.e. off-study Aspirin, clopidogrel, ticlopidine)
Current major depression.
Current treatment in another clinical study
Note: Current or recent use of intra-articular, topical or inhaled glucocorticoid therapy is acceptable;
History of or current immunodeficiency disease or prior treatment compromising immune function
Current use of exogenous testosterone
Current use of tamoxifen, aromatase inhibitors, or SERMs for a breast cancer indication for at last six months
History or current evidence of hyperthyroidism that would increase metabolism of itraconazole
Known past or current malignancy other than inclusion diagnosis, except for:
Patients with current use of megestrol acetate (use within  days of day ) will be excluded
No current or active dermatologic diagnoses that would preclude interpretation of skin toxicities of BKM and BYL
Current or prior HTLV- associated inflammatory diseases, including but not limited to myelopathy, uveitis, arthropathy, pneumonitis, or a Sjogrens disease-like disorder
Any current -alpha reductase inhibitors (history of use >=  months prior to MRI is acceptable)
Serious inter-current medical illness which would interfere with the ability of the patient to carry out the treatment program
Patients who are not a candidate for an unrelated donor allogeneic HSCT based on the current institutional BMT program clinical practice guidelines; organ function criteria will be utilized per the current institutional BMT program clinical practice guidelines; there will be no restriction to study entry based on hematological parameters
Any patients with a history of tamoxifen or raloxifene use within two years of current DCIS diagnosis are not eligible
Current or history of clinically significant muscle disorders (e.g., myositis), recent unresolved muscle injury, or any condition known to elevate serum CK levels
Subjects with uncontrolled and significant inter-current illness.
Is a current smoker
Patients with history and/or current evidence of endocrine alteration of calcium-phosphate homeostasis
History or current evidence of
current or prior IV drug users,
current or prior IV drug users,
Known past or current malignancy other than inclusion diagnosis, except for:
Uncontrolled inter-current illness, per protocol.
History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions
Current use of or =<  weeks prior to registration of anti-androgens such as flutamide, estrogens, ketoconazole, finasteride, or megestrol acetate
Agree to allow the sponsor to collect data on all GBM-related treatments received after the patient comes off the current study, and to collect survival data after the patient comes off the current study.
Current history of neoplasm other than the entry diagnosis. Exceptions are:
Subjects who have a history or current evidence of malignant biliary obstruction requiring biliary stent.
Current use of exogenous hormones
Current use of clobetasol propionate
Current indwelling urinary stent
Prior or current treatment with a cMet inhibitor
Uncontrolled inter-current illness, per protocol
Subjects with a past or current diagnosis of another malignancy that will interfere with conduct of the trial; patients with past or current cancer diagnoses other than ACC are allowed to enroll if the investigator believes it will not interfere with trial conduct
No prior therapy with the exception of  cycle of chemotherapy based on current diagnosis and clinical condition
sexual abstinence (only if this is in line with the patient's current lifestyle)
Previous or current history of a myeloproliferative disease
Current use of megestrol acetate (Use within  days of Day )
Large cell transformation. However, subjects with a history of LCT but without current aggressive disease and no current evidence of LCT on pathology in skin and lymph nodes would be eligible.
Current treatment with nitrates
Are unable to discontinue current treatment for CTCL due to risk of progression
Current spontaneous urinary incontinence.
Current use of a prohibitive medication(s)
Current Spigelman Stage  or . (Refer to Appendix A for Modified Spigelman Score and Classification table).
A history of AEs with prior interleukin (IL)- or Interferon will not preclude subjects from entering the current study
Current enrollment in any other investigational treatment study
Prior therapy for advanced malignancy with no current curative option
Patients with previous history or current presence of neurological disorders (with the exception of myasthenia gravis), including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes.
Current uncontrolled hyperthyroidism
Patients with previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease and extra-pyramidal syndromes
Current carcinoma of the breast
current symptomatic radiation proctitis requiring creams;
certain heart problems, active or chronic infections, serious significant diseases, AIHA requiring treatment, other current cancer or within last  years
Duration and extent of current episode of AA
Current use of FWGE
Current use (within  days of day ) of megestrol acetate.
Current anticoagulant therapy (acetylsalicylic acid [ASA] =<  mg per day allowed)
Another current or previous malignancy within  years of study entry unless approved by the sponsor
Current or previous other malignancy within  years of study entry without sponsor approval
Current use of drugs with known cardiotoxicity
Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) episode of DVT and/or PE;
Treatment with therapeutic doses of an anticoagulant other than that used for pretreatment of the current (index) VTE episode prior to randomization;
Any other current malignancy
Known current or a history of hepatitis B or C virus, including chronic and dormant states, unless disease has been treated and confirmed cleared
Known past or current malignancy other than inclusion diagnosis, except for:
Current (within last month) use of chemotherapy for breast or other malignancy
Current (within last  months) use of radiation for breast or other malignancy
Recent (within last month) or current intensive manual lymphatic drainage (MLD) and/or short stretch bandage use
Any other current malignancy
Current enrollment in another clinical study.
Current use of any platelet functioning inhibitors (including aspirin) within  days of first on-study thrombokinetic study
Any prior or current malignancy or myeloproliferative or immunodeficiency disorder.
Any prior or current malignancy or myeloproliferative disorder.
Current or recent (within -months) use of lipid-lowering medication
Other current malignancy than the disease under study
Current diagnosis of primary cutaneous ALCL (those with systemic ALCL are eligible)
History or current evidence of hyperthyroidism that would increase metabolism of Itraconazole
Current or recent pregnancy (within  months),
Current diagnosis for depression, including treatment with an SSRI.
Known or suspected current diagnosis of non GCTB giant cell-rich tumors
Known or suspected current diagnosis of brown cell tumor of bone or Paget's disease
Any current renal replacement therapy
Untreated current severe depression; currently treated depression is permitted if treatment is stable
Current psychotherapy (regular appointment[s] with a psychologist, counselor, or therapist within the last  days)
History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder)
Recent or current participation in educational/behavioral intervention study with similar focus
Active and current use of illegal recreational drugs
Current venous thrombosis in either upper extremity or be on current anticoagulant therapy
Current (weekly) use of cannabis
Previous or current neurologic disease affecting the lower hemithorax or below
Patient is being treated with oxymetazoline for allergic rhinitis or has a disorder or current medication use likely to adversely affect normal functioning of the nasal mucosa
Subjects with a current or past history of schizophrenia will also be excluded
Consistent with previous chemoprevention adherence research, patients will be excluded due to the presence of the following psychiatric conditions:\r\n* A lifetime history of dementia (ICD  codes F-, F-, F-, F-);\r\n* A lifetime history of a psychotic disorder (ICD  codes: F-F-);\r\n* A current diagnosis of a manic episode (ICD  codes F-);\r\n* Current uncontrolled major depressive disorder (ICD  codes F-);\r\n* A current diagnosis of any mental and behavioral disorders due to psychoactive substance use (excluding nicotine-related diagnoses) (ICD  codes: F- F-, except for nicotine-related diagnoses); and,\r\n* Current intoxication
Current treatment with pregabalin
Current evidence of cardiac arrhythmias defined as corrected QD interval (QTc) >=  mm/sec
Current vaginal infection
Failed to receive satisfactory improvement from one prior antidepressant medication at or above the minimal effective dose and duration in the current depressive episode
Current use of insulin or sulfonylureads for glycemic control, or history of ketoacidosis
Current smoker of >=  cigarettes per day, on average
Patients who are current meditation practitioners
Current or previous neurological disease, which may adversely affect swallowing
Current use of antipsychotics
All subjects must be willing to be monitored for adequacy of nutritional intake during the intervention, as is the current standard of clinical practice
Current use of (other N-methyl D-aspartate [NMDA] antagonists) amantadine, ketamine, or dextromethorphan
Current engagement in yoga practice >=  day per week
Current heterosexual or lesbian sexual partner
Current/recent (prior  months) pregnancy
History of or current neurological illness that significantly impacts cognition (e.g. stroke, multiple sclerosis, Parkinson's disease, Alzheimer's disease, head injury, epilepsy, etc)
Current use of a statin
Diagnosis of cardiovascular disease (CVD) with or without current statin use
Treatment with an anticoagulant for more than  days for the current blood clot, prior to randomization
Current use of a wearable PAM device as defined by use of PAM device in the last  months
Currently on  or more antidepressant or anti-anxiety therapies for mood disturbance of any kind; past use is allowed, just not current use
Free of current ethanol (ETOH) or drug abuse
Individuals with a current substance use disorder will also be excluded
ONCOLOGY NURSE: Planning to leave their current practice setting for other employment in the next  months
No current chemo or radio-therapy
Current or planned use of methoxyflurane, oral contraceptives, isotretinoin, penicillin, or ergot alkaloids
No current diagnosed untreated or unresolved oral candidiasis or oral herpes simplex virus (HSV) infection
No current use of glutamine or sucralfate powders at the time of registration (no washout required)
Current or past treatment with fluocinonide cream for vaginal dryness, itching, or dyspareunia
Known current vaginal infection
Any current axis I diagnosis
Deafness, current meditation practice (>  episodes or >  hour total, weekly), and current enrollment in a stress reduction program
The subject is a current smoker (has smoked within  weeks prior to surgery)
DONOR: Current use of statin drug
Previous or current neurologic disease affecting the lower hemithorax or below
Patient has not yet started current course of RT
Current skin disease or fungal infection of the feet;
Have no current doctor's diagnosis of anal condyloma, hemorrhoids, fissures, or anal cancer
Men with human immunodeficiency virus (HIV) and/or prior anal disease will be included given their increased risk for current disease
Current use of thienopyridine therapy (clopidogrel, prasugrel, or ticagrelor) that will be continued on study
current known Methicillin-resistant Staphylococcus Aureus (MRSA) colonization;
current known Vancomycin Resistant Enterococcus (VRE) colonization;
current known immunologically-deficient disease conditions (not including recent chemotherapy);
Current treatment with tamoxifen or aromatase inhibitors
Current diagnosis or history of cardiac pre-excitation syndromes (e.g. Wolff-Parkinson-White)
Current or ex-smoker with at least  pack-year history
Current participation in another cancer chemoprevention study
Current smoker (i.e., at least  cigarettes/day)
Subjects who have not received the seasonal influenza vaccine in the current flu season and are not suspected to have had an influenza infection in the current flu season
Subjects who had or are suspected to have had an influenza infection in the current influenza season
Endorse current psychosis.
Current use of a retinol containing agent or any retinoid analogue drug within the last  days
Current sexually transmitted infection (STI) requiring treatment (women may participate after adequate treatment, at the discretion of the treating provider)
Current use of statin medication or statin use within  months of screen  visit
Current smoker
Prior history or current use of tamoxifen or anti-estrogen therapy
Current or prior advanced adenomas
Any history of current or prior rectal cancer
Current use of statin therapy
Current use of rifampin and digoxin
Current smoker
Treatment with intravesical BCG or chemotherapy for a patients current < T tumor during the  months prior to the current diagnosis
Any other current or previous malignancy
Current use of anti-coagulants
Current narcotic use
Current or ex-smoker with at least a -year pack history
Current use of >=  cigarettes/day
Current use of >=  alcoholic drinks/day
Current or history of anal or peri-anal carcinoma
Must be a former or current smoker
current smoker
Current treatment with the anticonvulsant depakote (at time of enrollment)
Severe/uncontrolled inter current illness within the previous  days prior to PET scan
Malignancy other than current disease under study
Current use of gabapentin or venlafaxine for hot flashes
Any patient with a current case of cellulitis
Ileostomy or hepatic resection during current cytoreductive surgery
Patients who have already started treatment for the current malignancy
Previous inclusion in the current study
Patient undergoing current or recent treatment within past  weeks or scheduled for any treatment that could results in changes of lesion appearance between the two study examinations. This would include, but not restricted to, the following: current or recent radiation therapy, surgery, starting or recent chemotherapy.
Current use of aromatase inhibitor as prevention or treatment for breast cancer
Current or recent use of reproductive hormone therapy, tamoxifen, aromatase inhibitor or other estrogen inhibitors within the last  days, which may affect biomarkers
Current ingestion of broccoli sprout extract, which may confound study results
Current or recent treatment for any malignancy within the last one year, which may affect biomarkers
Current diagnosis of gastroesophageal reflux disease (GERD) with grade >= 
History of current oropharyngeal dysphagia unrelated to cancer diagnosis (e.g. dysphagia due to underlying neurogenic disorder) (Arm  only)
Current smoker, or former smoker who has less than a -year quit history
current smoker of at least  cigarettes per day for at least  year
Subjects with a known current condition of substance addiction.
